Title: Steroids: Female Oral Contraceptives and Abortifacients
1Steroids Female Oral Contraceptives and
Abortifacients
2Topics
- Steroid Hormones
- Oral Contraceptives
- Abortifacient
- Ovulation
- Mechanism of Action Oral Contraceptives
- Mechanism of Action Abortifacients
- Male Hormonal Contraceptives
- Side Effects
- Future
3Steroid Hormones
- Steroids that act as hormones.
- Grouped into five groups by the receptor to which
they bind - Glucorticoids, mineralcorticoids, androgens,
estrogens, and progestagens. - Synthesized from cholesterol in the gonads and
adrenal glands. - Carried in the blood going to specific carrier
proteins (ex. Sex hormone binding globulin or
corticosteroid binding globulin).
4How do steroid hormones work?
- In cytoplasm they can undergo an enzyme-mediated
alteration like reduction, hydroxylation, or
aromatization. - The steroid binds to the specific receptor.
- The steroid receptor dimerizes
- The steroid-receptor ligand complex binds to
specific DNA sequences and induces transcription
of its target genes.
5Oral Contraceptives
- Medications taken by mouth for the purpose of
birth control. - They are a class of synthetic steroid hormones
that suppress the release of follicle-stimulating
hormone (FSH) and luteinizing hormone (LH) from
the anterior lobe of the pituitary gland. - FSH and LH are called gonadotropic hormones and
they stimulate the release of progesterone and
estrogen from the ovaries which are responsible
for modulating the menstrual cycle.
6History of Oral Contraceptives
- 1500 years ago papyrus inscriptions.
- Early 1900s- Ludwig Haberlandt coined the term
hormonal sterilisation. - Nov. 1921- Haberlandt presented his work.
- 1927- Haberlandt published
- 1929- Adolf Butenandt isolated the first female
sex hormone, estrone. - 1934- Butenandt isolated progesterone from pig
ovaries.
7History
- 1948- Russel Marker synthesized progesterone
using wild yam (Dioscorea). - 1951- Gregory Pincus, Margaret Sanger, et al.
began researching. - 1960- 1st pill introduced (Envoid 10mg)
- 1970 Introduction low dose or second generation
of OCS - 1980 biphasic or triphasic regimens
- 1990 3rd generation OCS
- (O P has less androgenic activity)
8Abortifacients
- A substance that induces abortion.
- Controversy over the use of them.
- Types
- Herbal (ex. Brewers yeast, vitamin C, wild
carrot, black cohosh, slippery elm, pennyroyal,
nutmeg, mugwort, papaya, vervain, etc.) - Pharmaceutical (Mifepristone and Misoprostol)
9History of Abortifacients
- Ancient Greece the colony of Cyrene had an
economy based on silphium. - All throughout history, herbs have been used as a
means of abortifaceints. - Modern days surgical methods and medications are
used.
10Ovulation
- Process in the menstrual cycle where a mature
ovarian follicle ruptures and discharges an egg
(ovum). - Ovulation is triggered by a spike in the amount
of Follicle-Stimulation Hormone (FSH)and
Luteinizing Hormone (LH) released from the
pituitary gland. - Gonadoptopin releasing hormone (GnRH) stimulates
the expression of LH and FSH.
11Mechanism of Action Oral Contraceptives
- Progesterone is the only naturally occurring
progestagen. - All have antiestrogenic and antigonadotropic
properties. - Differ in their affinity for progesterone
receptors and side-effects. - Only synthetic progestagens are used in oral
contraceptives.
12Mechanism for Oral Contraceptives
- Progesterone (aka Progestagen)
Norethisterone
Norethynodrel
Synthetic Progesterones
Levonorgestrel
Chlormandinone acetate
13Mechanism of Action Oral Contraceptives
- There are two progesterone receptors PR-A and
PR-B. - Both have AF-1 and AF-2 transactivation domains.
- Since the ligand-binding domains are identical,
there is no difference in ligand binding. - Upon binding to progesterone, the receptors are
phosphorylated and form dimers that bind with
high selectivity to progesterone response
elements (PREs) located on target genes. - Transcriptional activation occurs after
recruitment of co-activators like SRC-1 in order
to have histone acetylase activity. - This increases the accessibility of general
transcriptional proteins to the target promoter.
14Mechanism of Action Oral Contraceptives
Gonadropin-releasing hormone
- Progestins
- Progestin-Only Contraceptive
- In the stomach, ovulation is inhibited by
suppressing function of the hypothalamic-pituitary
-ovarian axis. - It then modifies the midcycle surges of
luteinizing hormone (LH) and follicle-stimulation
hormone (FSH). - In the ovaries, hormone production is decreased.
- There are modifications made to the ovaries that
are unfavorable to implantation and the cervical
mucus is thickened. - Also, it inhibits sperm action.
LH, FSH
15Mechanism of Action Oral Contraceptives
- In oral contraceptives, the estrogens mainly used
are mestranol and ethinyl estradiol. - It is produced in the ovaries by FSH and LH.
- Too much estrogen can cause side effects such as
stroke, deep vein thrombosis, invasive breast
cancer, heart attack, etc.
16Mechanism of Action Oral Contraceptives
- Composed of 4 rings.
- The phenolic A ring is the principle structure
that is responsible for selective, high-affinity
binding to both receptors. - Sterodial estrogens arise from androstendione or
testosterone by aromatization of the A ring. - Reaction is catalyzed by a cytochrome P450
monooxygenase enzyme complex that uses NADPH and
oxygen as co-substrates.
17Mechanism of Action Oral Contraceptives
- Act primarily on the pituitary to control the
amplitude of gonadtropic pulses and contribute to
the amplitude of GnRH pulses secreted by the
hypothalamus. - They also inhibit gonadotropin (LH and FSH)
release during the menstrual cycle, but then they
have a mid-cycle stimulatory action that
increases the amount released causing LH to surge.
18Mechanism of Action Oral Contraceptives
- The hormone enters the cell and binds to an
estrogen receptor (ESR 1, ESR 2). - Binding causes a conformational change and causes
receptor to dimerize which increases the affinity
and rate of receptor binding to DNA. - ER dimer binds to estrogen response elements
located in the promoter region of target genes
where it then can regulate many of the same
target genes.
19Mechanism of Action Oral Contraceptives
- Estrogen Progestins
- (aka Combination Oral Contraceptives)
- Progestins bind to albumin and sex hormone
binding globulin in plasma then diffuse into cell
cytoplasm - Estrogen is lipid soluble and thus diffuses.
- Once in the cell, they regulate the transcription
of specific genes in the uterus. - Actions of hormones are mediated by their hormone
receptors which are nuclear transpcription
factors whose transcriptional regulartory
activity is mediated by the binding of the
specific steroid to these molecules. - Once the receptors bind hormone, they bind to
cis-acting sequences in the promoter region of
responsive genes and regulate transcription of
these genes.
20Mechanism of Action Oral Contraceptives
- Estrogen Progestin (aka Combination Oral
Contraceptives)
- The progestin negative feedback decreases the
frequency of GnRH released. - This decreases the release of FSH and LH which
inhibit follicle development. - Estradial levels do not increase (no positive
feedback). - In addition it decreases the amount of and
viscosity of the cervical mucus, inhibiting sperm
penetration. - Estrogen also contributes to decreasing the
amount of FSH produced by negative feedback on
the anterior pituitary. - No ovulation occurs as a result
21Mechanism of Action Oral Contraceptives
- Estrogen Progestin (aka Combination Oral
Contraceptives)
- Monophasic
- Same amount of estrogen and progestin in each
active pill. - Classified by estrogen level
- Low dose (20 mcg)
- Regular dose (30-35 mcg)
- High dose (50 mcg)
- Biphasic
- Alter the level of hormones once during the
menstrual cycle. - Same amount of estrogen but halfway through the
cycle, progestin is increased. - Triphasic
- 3 different doses of hormones.
- Depending on brand, estrogen may increase.
22Types of Oral Contraceptives
- Progesterone-Only
- Evonid
- Minipill
- Monophasic
- Yasmin
- Biphasic
- Necon
- Triphasic
- Cyclessa (100 ug, 125 ug, or 150 ug desogesterl)
- Ortho Tri-Cyclen Lo
- Tri-Norinyl
23Mechanism of Action Abortifacients
- Mifepristone (aka RU-486)
- It is a competitive receptor antagonist in the
presence of progesterone at the progesterone
receptor. - It causes the decidual degeneration which leads
to trophoblast detachment. - Results in decreased production of Human chronic
gonadotropin (hCG), which causes decreased
production of progesterone by the corpus luteum.
- Since pregnancy is dependant on progesterone
production by the corpus lutenum, pregnancy is
terminated. - In addition it increases prostagladin release
from the uterine lining, increasing uterine
contractions and enhances the uterus sensitivity
to prostagladin.
24Mechanism of Action Abortifacient
- Methotrexate
- Blocks enzyme necessary for DNA synthesis, which
inhibits the growth of placental trophoblastic
cells.
25Mechanism of Action Abortifacient
- Misoprostol
- Synthetic protaglandin E1 analogue.
- Used in combination with Mifepristone and
Methotrexate. - Softens and dilates the cervix.
- Binds to myometrial cells to cause uterine
contractions which cause expulsion of the embryo.
26Abortifacients
- Plan-B
- Consists of two doses of the minipill (.75 mg
levonorgestrel per pill) separated by 12 hours. - Preven (Yuzpe)
- A two 2-pill doses of a high-dose oral
contraceptive (.25 mg of levonorgestrel and .05
mg of ethinyl estradiol per pill) separated by 12
hours.
27Other Types of Contraceptives
- Vaginal rings
- Nuvaring
- Transdermal
- Contraceptive patches
- Nestorone gel
- Intrauterine
- Progestasert
- Mirena
- Intramuscular
- Gravibinon
- Subcutaneous
- Norplant
28Male Contraceptives
- Still in clinical trials.
- Stopping the secretion of a mans reproductive
hormones in the brain and the testes to reduce or
block sperm is the ultimate goal.
29Side Effects
- Blood clots
- Heart attacks
- Stroke
- Cancer
- Depression
- Nausea
- Dizziness
- Stomach upset
- Headache
30Future
- Looking at reducing the risks involved with
taking the pill. - Using natural products.
- Vaccines
31Refrences
- Matthiesson, Kati L. and McLachlan Robert. Male
hormonal contraceptionconcept in sight? Human
Reproduction Update, Vol.12, No.4 pp. 463482,
2006 - Ferro, Valerie and Mann, Jamie. Recent
Developments in Female Hormonal Contraception.
Current Womens Health Reviews, 2005, 1, 105-118 - Benagiano, Giuseppe, Bastianelli, Carlo and
Farris Manuela. Contraception Today. ANNALS NEW
YORK ACADEMY OF SCIENCES - Orme, M.LE. The Clinical Pharmacology of Oral
Contraceptive Steroids. Br. J. clin. Pharmac.
(1982), 14, 31-42 - Mears, Eleanor. Clinical Trials of Oral
Contraceptives. British Medical Journal. Nov. 4.
1961 - http//www.contraceptiononline.org/contrareport/ar
ticle01.cfm?art160 - http//www.nytimes.com/learning/general/onthisday/
bday/0409.html - http//www.djerassi.com/CEcontraceptives/index.htm
l